1. Home
  2. FATE

as of 12-04-2025 3:46pm EST

$1.11
+$0.04
+3.61%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Chart Type:
Time Range:
Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 131.5M IPO Year: 2013
Target Price: $3.92 AVG Volume (30 days): 1.4M
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.32 EPS Growth: N/A
52 Week Low/High: $0.66 - $2.93 Next Earning Date: 11-13-2025
Revenue: $7,137,000 Revenue Growth: -46.92%
Revenue Growth (this year): -52.48% Revenue Growth (next year): -25.54%

AI-Powered FATE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 73.68%
73.68%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: